References
Appropriateness of oral clopidogrel for prehospital STEMI management
Abstract
Introduction:
Clopidogrel is an anticoagulant commonly used in the prehospital environment for the management of ST-elevation myocardial infarction (STEMI). Some ambulance services have incorporated this into their treatment regimens; however, others hold a variety of alternative pharmacological interventions.
Aims:
The purpose of this study is to examine and determine the pharmacological efficacy and safety of clopidogrel in the management of patients with STEMI and assess whether ambulance services should use the drug as part of standard practice.
Methods:
A literature review was conducted to identify articles relating to the administration of clopidogrel in the prehospital setting. Fourteen peer-reviewed journal articles and eight clinical practice guidelines from international ambulance services were included in this review.
Results:
According to this literature review, clopidogrel has been deemed safe, effective and practical for widespread use in the prehospital environment for the management of STEMI. However, some disagreement has arisen over whether clopidogrel is a more favourable anticoagulant than ticagrelor and prasugrel.
Conclusion:
Anticoagulants such as clopidogrel should be strongly considered as a standard treatment regimen in the prehospital management of STEMI across international jurisdictions.
Cardiovascular disease is a major cause of mortality worldwide, and is directly related to the development of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) (Jiang et al, 2015). Globally, cardiovascular diseases (CVDs) are the number one cause of death (World Health Organization, 2017). Within the 17.5 million individuals who die from CVDs, four out of five deaths are caused by heart attacks and strokes (World Health Organization, 2017). Approximately 30% of patients with ACS experience STEMI, which is associated with a 5–15% inhospital mortality rate (André et al, 2014; Vercellino, 2017: 2).
Platelet aggregation and subsequent formation of a thrombus are pertinent components of STEMI development, and this highlights the importance of pharmacological platelet inhibition in the treatment of this condition (Jiang et al, 2015; US Food and Drug Administration (USFDA), 2019).
Subscribe to get full access to International Paramedic Practice
Thank you for visiting International Paramedic Practice and reading our archive of expert clinical content. If you would like to read more from the only journal dedicated to those working in emergency care, you can start your subscription today for just £48.
What's included
-
CPD Focus
-
Develop your career
-
Stay informed